Vaxxinity (VAXX) Stock Price, News & Analysis

Company Overview

Vaxxinity, Inc. is a biotechnology company focused on developing active immunotherapies, including vaccines designed to target proteins associated with neurodegenerative diseases. Its approach is intended to stimulate the immune system to generate antibodies against disease-related proteins, with the goal of slowing or preventing disease progression.

The company's pipeline has included UB-311, an investigational vaccine targeting amyloid-beta for Alzheimer's disease, and UB-312, an investigational vaccine targeting misfolded alpha-synuclein associated with Parkinson's disease and related disorders. Vaxxinity has also researched additional programs aimed at other neurological conditions, including therapies designed to address chronic pain and other diseases involving toxic proteins.

Vaxxinity was formed through the combination and rebranding of organizations associated with United Neuroscience and Covaxx. The company is headquartered in Dallas, Texas, and has conducted research and clinical development activities internationally. Mei Mei Hu, a co-founder, has served as the company's chief executive officer, while Lou Reese has been associated with the company's leadership and co-founded the business.

Key Stats

• Today's Range: $0.0001 to $0.0001
• 50-Day Range: N/A
• 52-Week Range: $0.00 to $0.20
• Volume: 2,373 shs
• Average Volume: 6,101 shs
• Market Capitalization: $12.68 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Vaxxinity Stock Analysis - MarketRank™

Vaxxinity scored higher than 5% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Vaxxinity.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Vaxxinity is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vaxxinity is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.37% of the float of Vaxxinity has been sold short.

Short Interest Ratio / Days to Cover

Vaxxinity has a short interest ratio ("days to cover") of 9.21.

Change versus previous month

Short interest in Vaxxinity has recently decreased by 0.33%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vaxxinity does not currently pay a dividend.

Dividend Growth

Vaxxinity does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added Vaxxinity to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Vaxxinity insiders have not sold or bought any company stock.

Percentage Held by Insiders

64.06% of the stock of Vaxxinity is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

82.95% of the stock of Vaxxinity is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 3/27/2023
• Today: 9/26/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:VAXX
• Previous Symbol: NASDAQ:VAXX
• CIK: 1851657
• Web: www.vaxxinity.com
• Phone: 254-244-5739
• Fax: N/A
• Employees: 90
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 126,750,000
• Free Float: 45,553,000
• Market Cap: $12.68 thousand
• Optionable: Not Optionable
• Beta: -76.44